1
Ying Song, 1 and Hui Wang 1 Objective. To examine the expression and changes in function of circulating CD4+CXCR5+FoxP3+ follicular Treg (Tfr) cells in patients with active rheumatoid arthritis (RA) and in patients with RA in stable remission, and to clarify the role of Tfr cells in the pathogenesis of RA.
Methods. Levels of Tfr cells and follicular helper T (Tfh) cells in the peripheral blood of 39 patients with active RA, 39 patients with RA in stable remission, and 33 healthy controls were detected by flow cytometry. The function of Tfr cells was measured by coculturing them with Tfh cells and B cells. Activated CD45RAÀFoxP3 high Tfr cells were also analyzed. Clinical indicators, including serum Ig and autoantibody levels, were tested, and correlations with Tfr cells were systematically analyzed. The Disease Activity Score in 28 joints (DAS28) was calculated, and correlation analysis with Tfr cells was conducted.
Results. The level of CD4+CXCR5+FoxP3+ Tfr cells and the Tfr cell:Tfh cell ratio in peripheral blood from patients with RA in stable remission were significantly increased compared with the same measures in patients with active RA and in healthy controls. The function of Tfr cells was enhanced, and the activated CD45RAÀFoxP3 high Tfr cell subset was increased in patients with RA in stable remission compared with healthy controls. Furthermore, the number of Tfr cells in RA patients was inversely correlated with IgG, rheumatoid factor, and anti-cyclic citrullinated peptide as well as with the DAS28.
Conclusion.
Circulating Tfr cells are increased as patients with RA achieve stable remission of disease, and increased Tfr cells can suppress autoimmunity in RA patients to stabilize their condition. Our results provide novel insight into RA pathogenesis.
Follicular helper T (Tfh) cells are one class of effector Th cells that play a critical role in the development of antigen-specific B cell immunity in vivo (1) (2) (3) (4) . Tfh cells are important for the formation of germinal center (GC) and humoral responses, which could help B cells by supporting class-switching, somatic hypermutation, and the generation of high-affinity antibodies (5, 6) . The humoral immunity mediated by CD4+CXCR5+FoxP3À Tfh cells was inhibited by CD4+CXCR5+FoxP3+ follicular Treg (Tfr) cells (7) . As one specialized subset of Treg cells, Tfr cells express CXCR5 that localizes to the GCs in mice and humans (7) . The expression of CXCR5 on Tfr cells depends on Bcl-6 (7, 8) . A lack of Tfr cells leads to more GC reactions in vivo (7) . The dysregulation of either Tfh or Tfr cells could result in abnormal GC responses and lead to the pathogenesis of autoimmune diseases (8) (9) (10) .
Rheumatoid arthritis (RA) is a common type of chronic systemic autoimmune disease that primarily affects the synovial joints of the hands and feet (11, 12) . The presence of autoantibodies such as rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibody is the representative characteristic of RA (13) (14) (15) . Several groups have investigated the role of Tfh cells in the pathogenesis of RA. Increases in circulating CXCR5+, CXCR5+ programmed death 1-positive (PD-1+), and CXCR5+ inducible costimulator-high CD4+ T cells have been reported in patients with RA (16) (17) (18) , which suggests that Tfh cells are involved in the disease process of RA. Increases in Tfh cells have been reported to be positively associated with disease scores as well as with the presence of anti-CCP antibodies (16) (17) (18) . Meanwhile, other studies showed no difference in circulating levels of Tfh cells between RA patients and healthy controls (19, 20) . However, until now, information about the expression of Tfr cells in peripheral blood of humans has been limited, and there are few studies concerning circulating levels of Tfr cells in patients with RA. The role of Tfr cells in the pathogenesis of RA remains unclear.
In the current study, we aimed to elucidate the expression and significance of circulating CD4+CXCR5+ FoxP3+ Tfr cells during the process of RA pathogenesis. We measured Tfr and Tfh cell levels in the peripheral blood of RA patients with active disease, patients with RA in stable remission, and healthy controls and detected changes in the frequency of Tfr cells and in the Tfr cell: Tfh cell ratio in these 2 groups of RA patients compared with healthy controls. We also tested the ability of Tfr cells to suppress Tfh cells during RA. The composition of Tfr cells according to the expression of CD45RA and FoxP3 was studied, and CD45RAÀFoxP3 high subsets were compared as well. In addition, relationships between CD4+CXCR5+FoxP3+ Tfr cells and serum immunoglobulin levels, serum autoantibody levels, and the Disease Activity Score in 28 joints (DAS28) (21) were systematically analyzed to clarify the clinical significance of Tfr cells during RA pathogenesis.
PATIENTS AND METHODS
Patients. The study included 78 patients with a diagnosis of RA according to the 1987 revised criteria of the American College of Rheumatology (22) who came to the outpatient rheumatology office of Peking University People's Hospital from October 2015 to November 2017. These included 39 patients with active RA (any joint with active disease or any sign of systemic disease) and 39 patients with disease in stable remission for no fewer than 3 consecutive months according to the 2014 update of the treat-to-target recommendations, in which clinical remission is defined as the absence of signs and symptoms of significant inflammatory disease activity (23) . We obtained blood samples from the patients for routine blood tests, and the remaining blood was used in the current study. We excluded patients with irrelevant chronic diseases and those with other autoimmune diseases. None of the patients studied had received any glucocorticoid and/ or immunosuppressive drug treatments within 1 month. The control group included 33 healthy individuals who had undergone physical examination in the hospital and who were generally matched by age and sex to the RA patients. Within the group of patients with active RA, we followed up 13 who had undergone a course of treatment with conventional disease-modifying antirheumatic drugs (DMARDs), including methotrexate, sulfasalazine, and leflunomide and analyzed their levels of CXCR5+FoxP3+ and CXCR5+ cells 1-3 months after the treatment.
The study received ethics approval (no. 2016PHB076-01) from the Ethics Committee of Peking University People's Hospital. The research was performed in accordance with the ethical standards of the Declaration of Helsinki. Informed consent was obtained from each subject.
Measurement of clinical indicators. White blood cells (WBCs) and lymphocytes were measured using a Sysmex XE-2100 instrument (Toa Medical Electronics). IgG, IgA, IgM, and RF were measured using an IMMAGE 800 instrument (Beckman Coulter). Autoantibodies were determined by indirect immunofluorescence using a Sprinter XL instrument (Euroimmun). The erythrocyte sedimentation rate (ESR) was measured using a Vacuette ESR System (Greiner Bio-One). Disease activity was assessed by the DAS28 using the ESR, as previously reported (24) .
Flow cytometry. Mononuclear cells were acquired from 2 ml of peripheral blood by Ficoll separation (Ficoll-Paque; Pharmacia) and then were stained for surface markers for 30 minutes in phosphate buffered saline (PBS) containing fluorescent antibodies. Cells were then washed twice with PBS. For intracellular FoxP3 staining, we used a Transcription Factor Staining Buffer Kit (Tonbo) according to the manufacturer's instructions. After fixation and permeabilization, anti-FoxP3 was incubated with the fixed cells for 30 minutes. Samples were analyzed on a FACSCanto II instrument (BD Biosciences). Isotype-matched control antibodies were used during flow cytometric analysis. All antibodies used in this research were purchased from BioLegend. Tfr cells were sorted from 8-10 ml of peripheral blood using a FACSAria II sorter (BD Biosciences). The culture system has been described previously (25) . One hundred microliters (2 9 10 4 cells) of blood Tfh cell suspension and 100 ll (2 9 10 4 cells) of blood memory B cell suspension from healthy controls were put into each well in a 96-well round-bottomed plate. We then added 1 9 10 4 Tfr cells sorted from RA patients or healthy individuals together with staphylococcal enterotoxin B (SEB; Sigma) to the culture at a final concentration of 1 lg/ml. Finally, we incubated the plates at 37°C in a 5% CO 2 atmosphere for 6 days for the culture with memory B cells (25) . Supernatants were harvested to measure IgM, IgG, and IgA concentrations using an enzymelinked immunosorbent assay (ELISA) kit (BioLegend).
Statistical analysis. Sex differences among groups were compared using a chi-square test. Age, WBC, and lymphocyte differences among groups were evaluated by analysis of variance. Results between different groups or between different subsets of cells were compared using Student's t-test for values that followed a Gaussian distribution and using the Mann-Whitney test for values that did not follow a Gaussian distribution. Spearman's correlation analysis was used to examine the relationship between CXCR5+FoxP3+ Tfr cells and clinical variables. All analyses were carried out using GraphPad Prism software.
RESULTS
Increased circulating CD4+CXCR5+PD-1 high Tfh cells in RA patients. To investigate the potential role of Tfr cells during RA pathogenesis, 39 patients with active RA, 39 patients with RA in stable remission, and 33 healthy subjects were recruited in this study. Their demographic and clinical characteristics are shown in Table 1 . There was no significant difference in the distribution of age and sex among the 2 groups of patients and the controls. Numbers of WBCs and lymphocytes also did not differ significantly among the groups. We obtained peripheral blood samples from the RA patients and controls and extracted mononuclear cells. We first characterized the numbers of CD4+CXCR5+ and CD4+CXCR5+PD-1 high Tfh cells in these subjects by flow cytometric analysis. As shown in Figure 1 , the percentages of CXCR5+ and CXCR5+PD-1 high Tfh cells in CD4+ cells were analyzed, and absolute numbers of these cells were also calculated. We found that the percentages and numbers of both CD4+CXCR5+ and CD4+CXCR5+PD-1 high Tfh cells in RA patients were significantly greater than those in healthy controls. Furthermore, there were no significant differences in Tfh cell frequency and number between patients with active RA and patients with RA in stable remission.
Increased CD4+CXCR5+FoxP3+ Tfr cells in the peripheral blood of patients with RA in stable remission. To clarify changes in Tfr cells from RA patients, we stained lymphocytes with antibodies to CD4, CXCR5, and FoxP3 and analyzed CD4+CXCR5+FoxP3+ Tfr cells by flow cytometry (Figure 2A ). Percentages and absolute numbers of CXCR5+FoxP3+ Tfr cells in the 3 groups were calculated and are shown in Figure 2B . Figure 2C , the ratio of CXCR5+FoxP3+ cells to CXCR5+ cells was also significantly elevated in patients with RA in stable remission. The ratios did not differ significantly between patients with active RA and healthy controls. We also compared levels of CD4+CXCR5ÀFoxP3+ cells among groups ( Figure 2D ) and found that levels of CD4+CXCR5ÀFoxP3+ cells were decreased in both groups of RA patients compared with controls, which suggests that Tfr cells but not other Treg cells are specifically altered in patients with RA in stable remission.
Finally, we followed up 13 patients with active RA who had undergone treatment with DMARDs and analyzed and compared levels of CXCR5+FoxP3+ and CXCR5+ cell subsets in these patients before and after treatment with DMARDs (see Supplementary Figure 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40430/abstract). We found that the percentages of CXCR5+FoxP3+ cells were increased after treatment, and Tfr cell:Tfh cell ratios were also elevated, while the DAS28 was decreased. However, levels of CXCR5+ cells were not significantly altered.
Enhanced suppressive capacity of circulating Tfr cells in patients with RA in stable remission. We compared the abilities of circulating Tfr cells to suppress Tfh cells and B cells from the 3 groups. CD4+CXCR5+ CD25 high CD127
low Tfr cells were sorted from the peripheral blood mononuclear cells of patients or healthy controls, and 92-95% of these cells were confirmed to express FoxP3 in both patients and healthy controls. These Tfr cells were then cocultured with memory B cells and CD4+CXCR5+CD25 À/low Tfh cells for 6 days with SEB in the culture (25) . Supernatant was then harvested, and IgM, IgG, and IgA concentrations were measured by ELISA (Figure 3 RA. Therefore, these results suggested that the suppressive capacity of circulating Tfr cells was relatively enhanced in patients with RA in stable remission.
Increased CXCR5+CD45RAÀFoxP3
high Tfr cells in peripheral blood from patients with RA in stable remission. FoxP3+ Treg cells in human peripheral blood could be We next considered the change in each fraction of CXCR5+FoxP3+ Tfr cells in the 3 groups. Representative low Tfr cells were sorted from patients with active RA (n = 10), patients with RA in stable remission (n = 10), and healthy controls (n = 10). Memory B cells and Tfh cells were cocultured with these Tfr cells for 6 days, and then supernatants were harvested to measure IgG, IgA, and IgM concentrations. Ig levels were measured in triple wells, and mean values were compared. Symbols represent individual subjects; bars show the mean AE SEM. * = P < 0.05; ** = P < 0.01; *** = P < 0.001. See Figure 1 for other definitions.
716
LIU ET AL fluorescence-activated cell sorting plots of CD45RA and FoxP3 expression within the CD4+CXCR5+FoxP3+ subset are shown in Figure 4 . The percentages and absolute numbers of CXCR5+CD45RAÀFoxP3 high cells (fraction II) in the 3 groups were calculated. We found that the percentages and absolute numbers of CXCR5+CD45RAÀ FoxP3 high cells were significantly increased in patients with RA in stable remission compared with patients with active RA and healthy controls. Levels of CXCR5+CD45RAÀ FoxP3 high cells were also increased in patients with active RA compared with healthy controls. However, there was no significant difference among the 3 groups for the fraction I and fraction III subsets (data not shown).
Negative correlation of CXCR5+FoxP3+ Tfr cells with IgG, anti-CCP, and RF. To explore the clinical significance of increased circulating CXCR5+FoxP3+ Tfr cells in RA patients, we conducted correlation analysis between CXCR5+FoxP3+ Tfr cells (both percentage and absolute number per liter) and clinical indicators in all RA patients (those with active disease and those with disease in stable remission), including the ESR, IgG, IgA, IgM, RF, and autoantibodies. We found significant inverse high follicular Treg (Tfr) cells in the 3 groups of subjects. Symbols represent individual subjects; bars show the mean AE SD. * = P < 0.05; ** = P < 0.01; *** = P < 0.001. R1 = region 1 (see Figure 1 for other definitions).
correlations between CXCR5+FoxP3+ cells (both the percentage and absolute number) and IgG, anti-CCP, and RF (r < 0, P < 0.05) ( Figure 5A ). For other indicators, however, the correlations were not significant. We also conducted correlation analysis between CXCR5+
CD45RAÀFoxP3
high cells and clinical indicators (see Supplementary Table 1 , available at http://onlinelibrary.wiley. com/doi/10.1002/art.40430/abstract). We found that the percentages of these cells were negatively correlated with IgA levels, and absolute numbers of these cells were (see Supplementary Table 2 , http://onlinelibrary.wiley.com/doi/10.1002/ art.40430/abstract) and found that only CD4+CXCR5À FoxP3+ Treg cells were negatively correlated with IgM, but the correlation was weak (r = À0.2369).
Inverse correlation of CXCR5+FoxP3+ Tfr cells with RA severity. We next examined the relationship between circulating CXCR5+FoxP3+ Tfr cells and RA severity. We chose the DAS28 as a reflection of disease severity. We conducted correlation analysis between CXCR5+FoxP3+ cells (both percentage and absolute number per liter) and the DAS28 and found that the DAS28 was inversely correlated with CXCR5+FoxP3+ Tfr cells (r < 0, P < 0.05), for both the percentage and absolute number ( Figure 5B ). These results suggest a potential relationship of circulating Tfr cells with RA disease severity. We also conducted correlation analysis between CXCR5+CD45RAÀFoxP3 high cells and the DAS28 (see Supplementary Table 1 , http://onlinelibrary.wiley.com/doi/ 10.1002/art.40430/abstract), and we found that both the percentage and absolute number of these cells were negatively correlated with DAS28 scores. Correlations between Treg cells and the DAS28 were also analyzed (see Supplementary Table 2 , http://onlinelibrary.wiley.com/doi/10.1002/ art.40430/abstract). There were no significant correlations between Treg cells and the DAS28, both for CD4+ CXCR5ÀFoxP3+ cells and for CD4+FoxP3+ cells.
DISCUSSION
In this study, we demonstrated that both the level of CXCR5+FoxP3+ Tfr cells and the Tfr cell:Tfh cell ratio were increased in peripheral blood from patients with RA in stable remission. In addition, the ability of Tfr cells to suppress Tfh cells was enhanced, and activated CD45RAÀ FoxP3 high Tfr cell subsets were increased in patients with RA in stable remission compared with healthy controls. Furthermore, we proved that CXCR5+FoxP3+ Tfr cells were inversely correlated with related clinical indicators, including IgG, RF, and anti-CCP, and that Tfr cells in the periphery were also inversely correlated with the DAS28 in RA patients. Our data have significant implications for the role of circulating Tfr cells in RA pathogenesis.
Tfh cells play a critical role in the development of antigen-specific B cell immunity (1-6). Numerous groups have investigated the role of Tfh cells in the pathogenesis of RA (5, 6) . Increases in circulating CXCR5+, CXCR5+ PD-1+, and CXCR5+PD-1 high Tfh cells have been reported in patients with RA (16) (17) (18) , and our findings are in accordance with those results. The humoral immunity mediated by Tfh cells was inhibited by Tfr cells (7) . There have been few studies concerning the role of circulating Tfr cells in autoimmune diseases. The frequency of CD4+CXCR5+FoxP3+ Tfr cells in the peripheral blood of patients with ankylosing spondylitis (AS) was reported to be significantly increased compared with that in the peripheral blood of healthy controls (27) . The number of CD4+CXCR5+FoxP3+ Tfr cells in patients with newly diagnosed systemic lupus erythematosus was significantly lower than the number in healthy controls (28) . Until now, there were few studies of the expression of circulating Tfr cells from RA patients. Macdonald and colleagues recently studied changes of Tfh and Tfr cells from patients with autoimmune diseases and suggested that the frequency of Tfr cells was increased in RA patients (29) , but their research lacked detailed disease staging studies. We found an increase of CXCR5+FoxP3+ Tfr cells in patients with RA in stable remission, which is similar to the situation in AS patients. Considering that the frequency of Tfh cells in RA patients is also elevated, we calculated the Tfr cell:Tfh cell ratio and found that it was also increased in patients with RA in stable remission, which proves that Tfr cells are increased relative to Tfh cells during RA pathogenesis.
Interestingly, we found that CXCR5ÀFoxP3+ Treg cells were decreased in RA patients, which suggests that Tfr cells are specifically altered in patients with RA in stable remission. We also studied the composition of Tfr cells, and the percentage of CXCR5+CD45RAÀ FoxP3 high cells was significantly decreased compared with the percentage of Treg cells (see Supplementary  Figure 2 , http://onlinelibrary.wiley.com/doi/10.1002/art. 40430/abstract). These results suggest that the function of circulating Tfr cells was altered compared with the function of circulating Treg cells. The detailed mechanism underlying the difference between the function of Tfr cells and the function of Treg cells needs to be clarified in the future. In addition, circulating CXCR5+CD45RAÀFoxP3 high cells were increased in patients with RA in stable remission, which suggests that these activated Tfr cells are elevated in vivo in RA patients compared with controls, and we speculate that these activated Tfr cells could help to inhibit the excessive autoimmune response in vivo.
We observed that higher levels of CXCR5+FoxP3+ Tfr cells were correlated with lower levels of IgG in RA patients, which suggests that circulating Tfr cells were likely to play immunosuppressive roles during RA. These CXCR5+FoxP3+ Tfr cells may suppress excessive autoimmune reactions. Notably, anti-CCP and RF levels were inversely correlated with circulating Tfr cells, which suggests that Tfr cells are important for suppressing autoantibody production and B cell-mediated autoimmunity during RA. We further analyzed the relationship between Tfr cells and RA severity and found that Tfr cells were inversely correlated with the DAS28, directly suggesting that Tfr cells play an immunosuppressive role during RA pathogenesis.
Thus, we assume that during RA pathogenesis, peripheral Tfr cells were gradually increased and played an important role in inhibition of the autoimmune response. In addition, elevated expression of Tfr cells can inhibit the production of autoantibodies, which in turn inhibits development of RA disease, making it possible for RA patients to achieve stable remission of disease. Our study still has limitations. Our research is based on small numbers of patients, and further multicenter research should be performed to better support our conclusions. The detailed mechanism of increased Tfr cells needs to be further researched. Tfr cells in GCs and synovial fluid of RA patients should also be studied thoroughly.
